Diabetes Devices Market is projected to grow to US$ 64.8 billion by 2033 | Tandem Diabetes Care, Insulet Corporation, Nipro Corporation, Medtronic plc, Terumo Corporation

The diabetes devices market was valued at US$ 33.4 billion in 2024 and is projected to grow to US$ 64.8 billion by 2033, registering a compound annual growth rate (CAGR) of 7.7% over the forecast period from 2025 to 2033.

The Diabetes Devices Market report by DataM Intelligence provides comprehensive insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. By combining qualitative and quantitative research methodologies, the firm delivers in-depth reports that help clients navigate complex market dynamics, drive strategic growth, and seize new opportunities in an ever-evolving global landscape.

Download your exclusive sample report today: (corporate email gets priority access): https://datamintelligence.com/download-sample/diabetes-devices-market?sg

Diabetes Devices Market Overview:

Diabetes devices are specialized medical tools designed to aid in the monitoring and management of diabetes. These devices play a crucial role in helping individuals regulate blood glucose levels, administer insulin, and maintain better control over their condition-ultimately minimizing the risk of severe complications such as cardiovascular diseases, kidney damage, and nerve-related issues. Their primary functions include blood glucose monitoring, insulin or medication delivery, and the provision of real-time data to support informed health decisions.

In recent years, the diabetes devices market has experienced notable growth, fueled by the rising global incidence of diabetes, increased awareness about disease management, and rapid technological innovations. In particular, the demand for continuous glucose monitoring (CGM) systems has surged, as these devices offer real-time tracking of glucose levels, enhancing patient convenience and improving treatment outcomes. As technology continues to evolve, the adoption of advanced diabetes management tools is expected to accelerate, further driving market expansion.

Diabetes Devices Market: Shifting Industry Trends:

Rising Prevalence of Diabetes and Innovative Product Launches Fuel Market Growth
The global diabetes devices market is experiencing strong growth, primarily driven by the rising incidence of diabetes and a surge in innovative product introductions. Over recent decades, the number of people living with diabetes has increased significantly. According to the International Diabetes Federation (IDF), approximately 536.6 million adults aged 20 to 79 were living with diabetes in 2021-equivalent to 1 in 10 individuals worldwide. This figure is projected to rise to 642.8 million by 2030 and 783.7 million by 2045, with more than 75% of cases occurring in low- and middle-income countries. This growing disease burden underscores the urgent need for accessible and effective diabetes management tools.

In response, manufacturers are introducing cutting-edge diabetes devices that enhance disease monitoring and treatment outcomes. These innovations are transforming diabetes care by improving usability, accuracy, and affordability-particularly in the areas of continuous glucose monitoring (CGM) and insulin delivery systems. Modern CGM devices allow patients to track glucose levels in real time, reducing dependence on traditional finger-prick methods and enabling better glycemic control.

A notable example of such innovation occurred in September 2024, when Senseonics Holdings, Inc. and Ascensia Diabetes Care received FDA approval for the Eversense 365 CGM system. This next-generation device is the first continuous glucose monitor approved for year-long use in adults with Type 1 and Type 2 diabetes. Representing a major advancement in diabetes technology, Eversense 365 offers extended wear, improved accuracy, and greater convenience for patients marking a significant milestone in the evolution of diabetes management solutions.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/diabetes-devices-market?sg

Strategic Key Players Driving the Diabetes Devices Market Forward: F. Hoffmann-La Roche Ltd, Abbott Laboratories, Medtronic plc, Terumo Corporation, B. Braun SE, Insulet Corporation, Nipro Corporation, Johnson & Johnson Services, Inc., Senseonics, Inc., Tandem Diabetes Care, Inc.

Research Methodology:

The global Diabetes Devices Market research report employs a comprehensive dual-source approach, integrating both primary and secondary data collection methods to ensure robust market analysis. Our research framework systematically evaluates multiple industry-influencing variables, including regulatory frameworks and government policies, prevailing market conditions, competitive intensity levels, historical performance data, current market positioning, technological innovations and disruptions, emerging industry developments, cross-sector business impacts, market volatility patterns, growth prospects, potential market barriers, and strategic challenges facing industry participants.

Segment Covered in the Diabetes Devices Market:

By Product Type (Blood Glucose Monitoring Devices, Insulin Delivery Devices)

By End-User (Hospitals, Specialty Clinics, Homecare Settings, Diagnostic Centers, Others)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?sg

Industry Recent Developments:

✅ XR Immersive Technologies acquires InsulinQ's CGM tech
In early 2025, XR Immersive Technologies acquired continuous glucose monitoring (CGM) technology from InsulinQ for roughly $3 million in stock, issuing 4 million shares at $0.75/share. The deal aims to bring affordable, mobile-integrated CGM for underserved markets, including India.

✅ Embecta (ex‐BD diabetes spin-off) considering sale
Embecta manufacturer of insulin syringes, pen needles, and an insulin patch pump in development has hired advisors to explore a potential sale, likely to private equity, given its depressed valuation (~$879M market cap) and flat financial performance.

✅ CeQur raises $120M for wearable patch-driven insulin delivery
In January 2025, CeQur, maker of the CeQur Simplicity wearable insulin patch, raised $120 million in funding to accelerate commercialization and global expansion.

Regional Analysis for Diabetes Devices Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Most Frequently Asked Questions in the Diabetes Devices Market Research Industry:

➠ Who leads the Diabetes Devices industry and what's their competitive positioning regarding capacity, performance, and profitability?

➠ What growth opportunities and market challenges do Diabetes Devices market vendors face?

➠ Which segments show the highest growth potential and market share distribution?

➠ What factors are driving or limiting Diabetes Devices market growth?

➠ What are the dominant sales and distribution strategies in the Diabetes Devices industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.